Inhalable liposomes of Glycyrrhiza glabra extract for use in tuberculosis: formulation, in vitro characterization, in vivo lung deposition, and in vivo pharmacodynamic studies

References

• Sandhu GK. Tuberculosis: current situation, challenges and overview of its control programs in India. J Global Infect Dis. 2011;3:143–150.
   PubMedGoogle Scholar
• Parumasivam T, Chang RY, Abdelghany S, et al. Dry powder inhalable formulations for anti-tubercular therapy. Adv Drug Deliv Rev. 2016;102:83–101.
   PubMed Web of Science ®Google Scholar
• Lall N, Meyer JJ. In vitro inhibition of drug-resistant and drug-sensitive strains of Mycobacterium tuberculosis by ethnobotanically selected South African plants. J Ethnopharmacol. 1999;66:347–354.
   PubMed Web of Science ®Google Scholar
• Newton SM, Lau C, Gurcha SS, et al. The evaluation of forty-three plant species for in vitro antimycobacterial activities; isolation of active constituents from Psoralea corylifolia and Sanguinaria canadensis. J Ethnopharmacol. 2002;79:57–67.
   PubMed Web of Science ®Google Scholar
• Pauli GF, Case RJ, Inui T, et al. New perspectives on natural products in TB drug research. Life Sci. 2005;78:485–494.
   PubMed Web of Science ®Google Scholar
• Gupta R, Thakur B, Singh P, et al. Anti-tuberculosis activity of selected medicinal plants against multi-drug resistant Mycobacterium tuberculosis isolates. Ind J Med Res. 2010;131:809–813.
   PubMed Web of Science ®Google Scholar
• Nair SS, Pharande RR, Bannalikar AS, et al. In vitro anti-mycobacterial activity of acetone extract of Glycyrrhiza glabra. J Pharm Pharmacog Res. 2015;3:80–86.
   Google Scholar
• Cao J, Chen X, Liang J, et al. Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra. Drug Metab Dispos. 2007;35:539–553.
   PubMed Web of Science ®Google Scholar
• Gao S, Hu M. Bioavailability challenges associated with development of anti-cancer phenolics. Mini Rev Med Chem. 2010;10:550–567.
   PubMed Web of Science ®Google Scholar
• Mignet N, Seguin J, Chabot GG. Bioavailability of polyphenol liposomes: a challenge ahead. Pharmaceutics. 2013;5:457–471.
   PubMedGoogle Scholar
• Pham DD, Fattal E, Tsapis N. Pulmonary drug delivery systems for tuberculosis treatment. Int J Pharm. 2015;478:517–529.
   PubMed Web of Science ®Google Scholar
• Muttil P, Wang C, Hickey AJ. Inhaled drug delivery for tuberculosis therapy. Pharm Res. 2009;26:2401–2416.
   PubMed Web of Science ®Google Scholar
• Gelperina S, Kisich K, Iseman MD, et al. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med. 2005;172:1487–1490.
   PubMed Web of Science ®Google Scholar
• Hoppentocht M, Hagedoorn P, Frijlink HW, et al. Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation. Eur J Pharm Biopharm. 2014;86:23–30.
   PubMed Web of Science ®Google Scholar
• Cunha L, Rodrigues S, Rosa da Costa AM, et al. Inhalable fucoidan microparticles combining two antitubercular drugs with potential application in pulmonary tuberculosis therapy. Polymers. 2018;10:636.
   Web of Science ®Google Scholar
• Chimote G, Banerjee R. Evaluation of antitubercular drug-loaded surfactants as inhalable drug-delivery systems for pulmonary tuberculosis. J Biomed Mater Res A. 2009;89:281–292.
   PubMedGoogle Scholar
• Gupta A, Sharma D, Meena J, et al. Preparation and preclinical evaluation of inhalable particles containing rapamycin and anti-tuberculosis agents for induction of autophagy. Pharm Res. 2016;33:1899–1912.
   PubMed Web of Science ®Google Scholar
• Misra A, Jinturkar K, Patel D, et al. Recent advances in liposomal dry powder formulations: preparation and evaluation. Expert Opin Drug Del. 2009;6:71–89.
   PubMed Web of Science ®Google Scholar
• Willis L, Hayes D, Mansour HM. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung. 2012;190:251–262.
   PubMed Web of Science ®Google Scholar
• Gradon L, Sosnowski TR. Formation of particles for dry powder inhalers. Adv Powder Technol. 2014;25:43–55.
   Web of Science ®Google Scholar
• Viswanathan V, Mukne AP. Development and validation of HPLC and HPTLC methods for estimation of glabridin in extracts of Glycyrrhiza glabra. J AOAC Int. 2016;99:374–379.
   PubMed Web of Science ®Google Scholar
• Laouini A, Jaafar-Maalej C, Limayem-Blouza I, et al. Preparation, characterization and applications of liposomes: state of the art. J Colloid Sci Biotechnol. 2012;1:147–168.
   Google Scholar
• Shur J, Saluja B, Lee S, et al. Effect of device design and formulation on the in vitro comparability for multi-unit dose dry powder inhalers. AAPS J. 2015;17:1105–1116.
   PubMed Web of Science ®Google Scholar
• Bai S, Gupta V, Ahsan F. Inhalable lactose-based dry powder formulations of low molecular weight heparin. J Aerosol Med Pulm Drug Deliv. 2010;23:97–104.
   PubMed Web of Science ®Google Scholar
• Marques MR, Loebenberg R, Almukainzi M. Simulated biological fluids with possible application in dissolution testing. Dissolut Technol. 2011;18:15–28.
   Web of Science ®Google Scholar
• Ramana LN, Sethuraman S, Ranga U, et al. Development of a liposomal nanodelivery system for nevirapine. J Biomed Sci. 2010;17:57–59.
   PubMed Web of Science ®Google Scholar
• Ong SGM, Ming LC, Lee KS, et al. Influence of the encapsulation efficiency and size of liposome on the oral bioavailability of griseofulvin-loaded liposomes. Pharmaceutics. 2016;8:25.
   PubMed Web of Science ®Google Scholar
• Aquino RP, Prota L, Auriemma G, et al. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cels. Int J Pharm. 2012;426:100–107.
   PubMed Web of Science ®Google Scholar
• Pai RV, Jain RR, Bannalikar AS, et al. Development and evaluation of chitosan microparticles based dry powder inhalation formulations of rifampicin and rifabutin. J Aerosol Med Pulm Drug Deliv. 2016;29:179–195.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Chang YX, Hu X, et al. Solid lipid nanoparticles for sustained pulmonary delivery of Yuxingcao essential oil: preparation, characterization and in vivo evaluation. Int J Pharm. 2017;516:364–371.
   PubMedGoogle Scholar
• Kaur J, Muttil P, Verma RK, et al. A hand-held apparatus for “nose-only” exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages. Eur J Pharm Sci. 2008;34:56–65.
   PubMed Web of Science ®Google Scholar
• Saraogi GK, Sharma B, Joshi B, et al. Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis. J Drug Target. 2011;19:219–227.
   PubMed Web of Science ®Google Scholar
• Labana S, Pandey R, Sharma S, et al. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int J Antimicrob Agents. 2002;20:301–304.
   PubMed Web of Science ®Google Scholar
• Mitscher LA, Park YH, Clark D, et al. Antimicrobial agents from higher plants, antimicrobial isoflavonoids and related substances from Glycyrrhiza glabra L. var. Typica. J Nat Prod. 1980;43:259–269.
   PubMed Web of Science ®Google Scholar
• Aoki F, Nakagawa K, Kitano M, et al. Clinical safety of licorice flavonoid oil (LFO) and pharmacokinetics of glabridin in healthy humans. J Am Coll Nutr. 2007;26:209–218.
   PubMed Web of Science ®Google Scholar
• Viswanathan V, Mukne AP. Nano-liposomes of Glycyrhiza glabra using quality-by-design approach: preparation, optimization and In vitro characterization. Br J Pharm Sci. In press.
   Google Scholar
• Liu Y, Luo X, Xu X, et al. Preparation, characterization and in vivo pharmacokinetic study of PVP-modified oleanolic acid liposomes. Int J Pharm. 2017;517:1–7.
   PubMed Web of Science ®Google Scholar
• El-Nesr OH, Yahiya SA, El-Gazayerly ON. Effect of formulation design and freeze-drying on properties of fluconazole multilamellar liposomes. Saudi Pharm J. 2010;18:217–224.
   PubMedGoogle Scholar
• Tang Y, Zhang H, Lu X, et al. Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation. Drug Deliv. 2015;22:608–618.
   PubMed Web of Science ®Google Scholar
• Hoppentocht M, Hagedoorn P, Frijlink HW, et al. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev. 2014;75:18–31.
   PubMed Web of Science ®Google Scholar
• De Boer AH, Hagedoorn P, Hoppentocht M, et al. Dry powder inhalation: past, present and future. Expert Opin Drug Deliv. 2017;14:499–512.
   PubMed Web of Science ®Google Scholar
• Chvatal A, Farkas Á, Balásházy I, et al. Aerodynamic properties and in silico deposition of meloxicam potassium incorporated in a carrier-free DPI pulmonary system. Int J Pharm. 2017;520:70–78.
   PubMedGoogle Scholar
• Mukne AP, Viswanathan V, Pharande RR, et al. Acute toxicity studies of nano-formulations of Glycyrrhiza glabra extract in Swiss Albino mice. World J Pharm Pharm Sci. 2017;6:820–829.
   Google Scholar